OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/07/26	JP¥20.00	+5.26%	221,234,000
09/07/26	JP¥19.00	0.00%	198,931,700
08/07/26	JP¥19.00	-9.52%	194,571,000
07/07/26	JP¥21.00	+5.00%	217,983,300
06/07/26	JP¥20.00	0.00%	183,177,800

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 07:30:00 10/07/2026 BST			5-day change	1st Jan Change
20.00 ^JPY	+5.26%		0.00%	-

23/06/25	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
27/04/25	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI

Market Cap	7.67B 47.5M 41.55M 38.33M 35.4M 67.17M 4.53B 68.3M 458M 180M 2.23B 178M 174M	P/E 2025	-8.97x	P/E 2026	-7.57x
Enterprise Value	5.58B 34.57M 30.24M 27.89M 25.76M 48.88M 3.3B 49.7M 333M 131M 1.62B 130M 127M	EV / Sales 2025	9.03x	EV / Sales 2026	7.39x
Free-Float	88.29%	Yield 2025 *	-	Yield 2026	-

23/06/25	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
27/04/25	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI
09/04/25	OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding	CI
29/04/24	Poland's Tusk calls prosecutor over potential Orlen scandal	RE
21/04/24	OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024	CI
04/04/24	OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor	CI
18/09/23	OncoTherapy Science, Inc.(TSE:4564) dropped from S&P Global BMI Index	CI
12/05/23	OncoTherapy Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
09/04/23	OncoTherapy Science, Inc. announced that it has received ¥95.95 million in funding	CI
23/03/23	OncoTherapy Science, Inc. announced that it expects to receive ¥95.95 million in funding	CI
27/04/21	OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
11/04/21	OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
14/01/19	OncoTherapy Science, Inc. announced that it has received ¥12.013 million in funding from Daiwa Securities Group Inc.	CI

14/05/24	Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	AQ
05/12/23	Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	AQ
13/09/22	OncoTherapy Science : Announcement of the Presentation of Interim Results for Phase I Clinical Study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer	PU
01/10/20	OncoTherapy Science : Japanese bio-venture starts development of COVID-19 peptide vaccine	AQ

OncoTherapy Science, Inc. Share Price

Stocks

4564

JP3202150003

Biotechnology & Medical Research

Valuation: OncoTherapy Science, Inc.

Chart: OncoTherapy Science, Inc.

Latest news : OncoTherapy Science, Inc.

Press Releases: OncoTherapy Science, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: OncoTherapy Science, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 day	+5.26%
Current month	+11.11%
1 month	+5.26%
3 months	-13.04%
6 months	-16.67%

1 week	19	21
1 month	18	21
Current year	18	34
1 year	18	34
3 years	15	64
5 years	15	111
10 years	15	338

Manager	Title	Age	Since
Junichi Shimada PSD	President	65	30/06/2022
Zehyon Paku PSD	President	50	04/12/2019
Yuka Yamane CTO	Chief Tech/Sci/R&D Officer	53	31/07/2012

Director	Title	Age	Since
Yuichi Komine BRD	Director/Board Member	54	31/08/2014
Zehyon Paku BRD	Director/Board Member	50	31/05/2018
Hatsuo Kato CHM	Chairman	82	31/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCOTHERAPY SCIENCE, INC.	+5.26%	0.00%	-31.03%	-44.44%	47.5M
ARGENX SE	-4.14%	-8.06%	+57.35%	+117.24%	54.63B
WUXI APPTEC CO., LTD.	+1.84%	-0.66%	+75.79%	+93.87%	54.88B
INSMED INCORPORATED	-2.24%	+3.59%	+19.60%	+466.72%	25.06B
BIONTECH SE	-1.60%	-6.21%	-19.69%	-14.84%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+47.70%	-0.11%	19.88B
GENMAB A/S	-3.19%	0.00%	+33.99%	-26.87%	17.55B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+195.12%	+357.18%	16.5B
EXELIXIS, INC.	-1.05%	+1.16%	+25.08%	+196.28%	14.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+53.81%	-	15.36B
Average	-0.08%	-0.25%	+45.77%	+127.22%	24.12B
Weighted average by Cap.	-0.91%	-1.46%	+55.03%	+137.75%

	2025	2026
Net sales	750M 4.64M 4.06M 3.75M 3.46M 6.57M 443M 6.68M 44.76M 17.58M 218M 17.43M 17.05M	808M 5M 4.38M 4.04M 3.73M 7.07M 477M 7.19M 48.22M 18.94M 235M 18.78M 18.37M
Net income	-815M -5.05M -4.41M -4.07M -3.76M -7.13M -481M -7.25M -48.64M -19.1M -237M -18.95M -18.53M	-910M -5.63M -4.93M -4.55M -4.2M -7.97M -537M -8.1M -54.31M -21.33M -265M -21.15M -20.69M
Net Debt	-833M -5.16M -4.51M -4.16M -3.84M -7.29M -492M -7.41M -49.71M -19.52M -242M -19.36M -18.94M	-2.09B -12.93M -11.31M -10.43M -9.64M -18.29M -1.23B -18.59M -125M -48.96M -608M -48.56M -47.5M